Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (29481)	11/24/1999 8:38:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Your post did not mention ONTAK: <<I would hope Lgnd has this info all completed now and will be ready to submit it immediately after receiving the approval letter. They should have a good idea what the FDA wants based on Panretin.>> ONTAK did take longer than expected, but it was a transition application (submitted by SRGN when they were out of money). The Panretin submission went smoothly. It was done professionally by LGND and I would expect the same for Targretin.